Spatial Survival Model for COVID-19 in México.

Publication date: Jan 24, 2024

A spatial survival analysis was performed to identify some of the factors that influence the survival of patients with COVID-19 in the states of Guerrero, McE9xico, and Chihuahua. The data that we analyzed correspond to the period from 28 February 2020 to 24 November 2021. A Cox proportional hazards frailty model and a Cox proportional hazards model were fitted. For both models, the estimation of the parameters was carried out using the Bayesian approach. According to the DIC, WAIC, and LPML criteria, the spatial model was better. The analysis showed that the spatial effect influences the survival times of patients with COVID-19. The spatial survival analysis also revealed that age, gender, and the presence of comorbidities, which vary between states, and the development of pneumonia increase the risk of death from COVID-19.

Open Access PDF

Concepts Keywords
Basel bayesian methodology
Chihuahua spatial correlation
Healthcare survival time


Type Source Name
disease MESH COVID-19
drug DRUGBANK Dacarbazine
drug DRUGBANK Tropicamide
disease MESH pneumonia
disease MESH death
drug DRUGBANK Coenzyme M
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO organization
disease IDO country
disease MESH hypertension
disease MESH obesity
disease MESH chronic kidney disease
disease VO population
disease VO effective
disease MESH dengue fever
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH leukemia
disease VO time
disease MESH AIDS
disease MESH tooth loss
disease MESH Viral Diseases
disease MESH Asthma
pathway KEGG Asthma
disease MESH COPD
disease IDO symptom
disease IDO process
disease MESH cardiovascular disease
drug DRUGBANK Indoleacetic acid
disease MESH morbidities
disease MESH metabolic diseases
disease MESH complications
disease MESH overweight
disease MESH fatal outcomes
disease MESH inflammation
disease MESH lifestyle factors
drug DRUGBANK Water
disease MESH colon cancer
disease MESH Glaucoma
disease IDO history
disease VO USA
drug DRUGBANK Serine
disease VO volume

Original Article

(Visited 1 times, 1 visits today)